Curcumin cuts triglycerides and LDL enough to matter clinically

Unhealthy blood lipid levels are a major risk factor for atherosclerotic cardiovascular disease, and interest in food-derived compounds that might help has long outrun clear answers. Curcumin, the compound derived from turmeric, has been tested in dozens of trials for effects on lipid metabolism, producing a stack of overlapping reviews with varying conclusions. This umbrella review set out to gather all of those reviews, add newly published trials, and settle what curcumin supplementation actually does to cholesterol and triglycerides, and whether the changes are large enough to matter for patients.

The authors searched electronic databases through the end of March 2023, without language restrictions, for systematic reviews and meta-analyses of randomised controlled trials comparing curcumin supplementation with placebo on total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. Twenty-six reviews met the inclusion criteria, from which 53 unique trials were re-pooled, and a fresh search added 19 more, bringing the updated meta-analysis to 72 trials. The team also judged whether the pooled changes reached minimally clinically important differences, the threshold at which a change is considered meaningful for patients.

Curcumin lowered LDL cholesterol by 5.84 mg/dL and triglycerides by 13.15 mg/dL, and both reductions reached the threshold for clinical importance. Total cholesterol fell by 7.76 mg/dL and HDL cholesterol rose by 2.4 mg/dL, but neither of those changes met the bar for clinical meaningfulness. Subgroup analysis showed greater lipid improvements in people with metabolic-related diseases, particularly type 2 diabetes. Enhanced-bioavailability forms of curcumin, supplementation lasting at least 8 weeks and combining supplementation with exercise were each associated with additional benefit, while the trials disagreed with each other substantially on every outcome.

By pooling 72 trials from across 26 prior reviews plus newer studies, this analysis sits near the top of the evidence hierarchy for curcumin and blood lipids, and it lands between the enthusiasts and the sceptics: genuine, clinically relevant effects on LDL and triglycerides, more marginal ones on total and HDL cholesterol. The heavy disagreement between trials, plausibly reflecting different formulations, populations and durations, keeps the exact effect sizes uncertain. It also suggests formulation matters, with enhanced-bioavailability versions showing greater benefit.

If triglycerides or LDL cholesterol are on your radar, this is a reason to regard curcumin as a supplement with real, if modest, pooled trial evidence behind it rather than pure turmeric hype. The clearest benefits appeared in people with existing metabolic conditions, with enhanced-absorption formulations and with use lasting at least 8 weeks. The wide disagreement between trials means individual results are hard to predict, and nothing here positions curcumin as a stand-in for prescribed lipid treatment.